Bionomics Limited, (BNOX): Price and Financial Metrics


Bionomics Limited, (BNOX): $4.00

-0.01 (-0.25%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BNOX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BNOX Stock Price Chart Interactive Chart >

Price chart for BNOX

BNOX Price/Volume Stats

Current price $4.00 52-week high $12.99
Prev. close $4.01 52-week low $3.51
Day low $3.98 Volume 1,574
Day high $4.20 Avg. volume 14,075
50-day MA $5.96 Dividend yield N/A
200-day MA $0.00 Market Cap 32.64M

Bionomics Limited, (BNOX) Company Bio


Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.


BNOX Latest News Stream


Event/Time News Detail
Loading, please wait...

BNOX Latest Social Stream


Loading social stream, please wait...

View Full BNOX Social Stream

Latest BNOX News From Around the Web

Below are the latest news stories about BIONOMICS LIMITED that investors may wish to consider to help them evaluate BNOX as an investment opportunity.

All Focus Shifts To Bionomics' PTSD Study After Anxiety Trial Disappoints

Bionomics Limited (NASDAQ: BNOX) announced results from its Phase PREVAIL study of BNC210 for the acute treatment of Social Anxiety Disorder (SAD), showing a miss on the primary endpoint. HC Wainwright, while downgrading the stock to Neutral from Buy, discussed the history of BNC210 and the PTSD program previously. The analyst writes that it has received baseline support from models of conditioned fear extinction and clinical effect from enhanced emotional recovery from CCK-induced panic attacks

Yahoo | December 19, 2022

Bionomics' Social Anxiety Disorder Study Fails To Meet Primary Endpoint

Bionomics Limited (NASDAQ: BNOX) announced results from its Phase PREVAIL study of BNC210 for the acute treatment of Social Anxiety Disorder (SAD). The trial enrolled 151 adult patients. The primary endpoint, measured by the change from baseline to the average of the Subjective Units of Distress Scale (SUDS) scores during a 5-minute Public Speaking Challenge, was not met in the BNC210-treated patients when compared to placebo. SUDS is a tool for quantifying the intensity of anxiety, fear, or dis

Yahoo | December 19, 2022

Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder

BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary EndpointSubjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to PlaceboBNC210 Demonstrated Favourable Safety and Tolerability Profile Consistent with Prior ExperienceCompany is Continuing Analysis of the Data and Evaluating Next Steps with Cash Runway into mid-2024 ADELAIDE, Australia, Dec. 18, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (B

Yahoo | December 19, 2022

Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer

Experienced biotech executive to lead the next phase of growthADELAIDE, Australia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it has appointed Spyridon “Spyros” Papapetropoulos, M.D. as

Yahoo | December 15, 2022

Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting

ADELAIDE, Australia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders, today announced it will present data on the development of an oral tablet formulation of BNC210 for the treatment of Social Anxiety Disorder (SAD) and data on the pharmacometr

Yahoo | December 2, 2022

Read More 'BNOX' Stories Here

BNOX Price Returns

1-mo -13.98%
3-mo -50.00%
6-mo N/A
1-year -64.38%
3-year N/A
5-year N/A
YTD -13.98%
2022 -62.95%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.64 seconds.